Breaking News Instant updates and real-time market news.

KMPH

KemPharm

$3.80

-0.3 (-7.32%)

, ACUR

Acura Pharmaceuticals

$1.18

-0.07 (-5.60%)

06:31
10/18/16
10/18
06:31
10/18/16
06:31

KemPharm enters licensing agreement with Acura Pharmaceuticals

KemPharm (KMPH) and Acura Pharmaceuticals (ACUR) announced that they have entered into a License Agreement whereby Acura will provide its proprietary Aversion Technology to KemPharm to use with its current and in-development immediate release opioid product candidates. Aversion Technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features and benefits for orally administered pharmaceutical drug products. The Agreement provided for an upfront cash payment of $3.5M to Acura at execution and grants KemPharm development and commercialization rights for up to three IR product candidates containing two of KemPharm's opioid prodrugs. Additional payments are provided in the Agreement should KemPharm exercise its option to use Acura's Aversion Technology with more than the three products. Acura is eligible to receive a royalty at a low single-digit rate based on commercial sales by KemPharm of all products developed under the Agreement. KemPharm will solely own the intellectual property resulting from any new product development.

KMPH

KemPharm

$3.80

-0.3 (-7.32%)

ACUR

Acura Pharmaceuticals

$1.18

-0.07 (-5.60%)

KMPH KemPharm
$3.80

-0.3 (-7.32%)

02/10/16
COWN
02/10/16
NO CHANGE
COWN
KemPharm's KP201 NDA accepted, says Cowen
Cowen said KemPharm's KP201 NDA has been accepted by the FDA and believes it will likely be the first hydrocodone/APAP product with abuse-deterrent claims. If approved, the firm's analyst expects clinicians will likely prescribe KP201 over other significantly more abusable options, driving significant share value from these levels.
05/06/16
OPCO
05/06/16
NO CHANGE
Target $11
OPCO
Outperform
KemPharm price target lowered to $11 from $28 at Oppenheimer
Oppenheimer analyst Rohit Vanjani lowered his price target for KemPharm to $11 from $28 given the higher risk of a non-approval or approval without AD labeling for the company's Apadaz after a negative FDA Advisory Committee meeting. Though panel members voted that Apadaz should get approved based on the bioequivalence data to the reference drug, the members voted against labeling it as an abuse-deterrent product, the analyst tells investors in a research note. However, Vanjani believes this will not be the "end of the story," reiterating an Outperform rating on the shares while he awaits further commentary from the FDA.
05/06/16
RBCM
05/06/16
NO CHANGE
RBCM
KemPharm price target lowered to $14 from $22 at RBC Capital
RBC Capital cut its price target on KemPharm after an FDA panel voted 16-4 to recommend approval of the company's Apadaz drug but voted 18-2 against inclusion of an abuse deterrent claim in the label. The firm says that the abuse deterrent label was the key to the drug's success. Nonetheless, the firm remains upbeat on the company's technology, and it keeps an Outperform rating on the shares.
ACUR Acura Pharmaceuticals
$1.18

-0.07 (-5.60%)

03/11/16
ROTH
03/11/16
INITIATION
Target $6
ROTH
Buy
Acura Pharmaceuticals re-initiated with a Buy at Roth Capital
Roth Capital analyst Michael Higgins re-initiated shares of Acura Pharmaceuticals with a Buy rating and $6 price target.
04/13/16
ROTH
04/13/16
NO CHANGE
Target $6
ROTH
Buy
Acura LTX-04 Fast Track designation not surprising, says Roth Capital
Roth Capital analyst Michael Higgins says the FDA designated Acura Pharmaceuticals' LTX-04 with Fast Track development, allowing an expedited review. Given the FDA's cautionary statements that current abuse deterrent formulations do not have impact on the primary form of abuse, swallowing too many opioids or taking them with alcohol, the designation is not surprising, but should alert to the importance of the Limitx technology, the analyst tells investors in a research note. Higgins reiterates a Buy rating and $6 price target.

TODAY'S FREE FLY STORIES

BMS

Bemis

$44.90

-0.28 (-0.62%)

20:30
06/22/17
06/22
20:30
06/22/17
20:30
Upgrade
Bemis rating change  »

Bemis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATUS

Altice USA

20:29
06/22/17
06/22
20:29
06/22/17
20:29
Initiation
Altice USA initiated  »

Altice USA initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

BBRY

BlackBerry

$11.06

0.41 (3.85%)

, FINL

Finish Line

$12.73

0.23 (1.84%)

20:25
06/22/17
06/22
20:25
06/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BBRY

BlackBerry

$11.06

0.41 (3.85%)

FINL

Finish Line

$12.73

0.23 (1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 23

    Jun

NBRV

Nabriva Therapeutics

$10.50

1.19 (12.78%)

20:22
06/22/17
06/22
20:22
06/22/17
20:22
Initiation
Nabriva Therapeutics initiated  »

Nabriva Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jul

WIX

Wix.com

$72.80

0.5 (0.69%)

20:20
06/22/17
06/22
20:20
06/22/17
20:20
Initiation
Wix.com initiated  »

Wix.com initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

OCLR

Oclaro

$9.44

-0.1 (-1.05%)

20:19
06/22/17
06/22
20:19
06/22/17
20:19
Initiation
Oclaro initiated  »

Oclaro initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

ACIA

Acacia Communications

$41.64

0.65 (1.59%)

20:19
06/22/17
06/22
20:19
06/22/17
20:19
Initiation
Acacia Communications initiated  »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

LITE

Lumentum

$62.45

-0.05 (-0.08%)

20:19
06/22/17
06/22
20:19
06/22/17
20:19
Initiation
Lumentum initiated  »

Lumentum initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 26

    Jun

LEJU

Leju

$2.46

0.07 (2.93%)

20:05
06/22/17
06/22
20:05
06/22/17
20:05
Downgrade
Leju rating change  »

Leju downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GCP

GCP Applied Technologies

$30.40

0.3 (1.00%)

20:04
06/22/17
06/22
20:04
06/22/17
20:04
Upgrade
GCP Applied Technologies rating change  »

GCP Applied Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PHM

PulteGroup

$24.04

-0.24 (-0.99%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
PulteGroup initiated  »

PulteGroup initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHI

D.R. Horton

$33.47

-0.5 (-1.47%)

19:58
06/22/17
06/22
19:58
06/22/17
19:58
Initiation
D.R. Horton initiated  »

D.R. Horton initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAA

CalAtlantic

$34.80

-0.34 (-0.97%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
CalAtlantic initiated  »

CalAtlantic initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BZH

Beazer Homes

$13.01

0.03 (0.23%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Beazer Homes initiated  »

Beazer Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTH

Meritage Homes

$40.40

-0.4 (-0.98%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Meritage Homes initiated  »

Meritage Homes initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOL

Toll Brothers

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Toll Brothers initiated  »

Toll Brothers initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$52.41

-0.84 (-1.58%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
Lennar initiated  »

Lennar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KBH

KB Home

$22.23

-0.1 (-0.45%)

19:57
06/22/17
06/22
19:57
06/22/17
19:57
Initiation
KB Home initiated  »

KB Home initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MHK

Mohawk

$242.70

-0.22 (-0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Mohawk initiated at Credit Suisse »

Mohawk initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBHS

Fortune Brands

$65.09

0.06 (0.09%)

19:27
06/22/17
06/22
19:27
06/22/17
19:27
Initiation
Fortune Brands initiated at Credit Suisse »

Fortune Brands initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JELD

JELD-WEN Holding

$34.60

-0.29 (-0.83%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
JELD-WEN Holding initiated at Credit Suisse »

JELD-WEN Holding…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$52.75

-1 (-1.86%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Installed Building Products initiated at Credit Suisse »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OC

Owens Corning

$66.42

-0.85 (-1.26%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Owens Corning initiated at Credit Suisse »

Owens Corning initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WHR

Whirlpool

$195.16

1.35 (0.70%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Whirlpool initiated at Credit Suisse »

Whirlpool initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$38.82

0.06 (0.15%)

19:26
06/22/17
06/22
19:26
06/22/17
19:26
Initiation
Masco initiated at Credit Suisse »

Masco initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.